Cor Vasa 2017, 59(3):e277-e281 | DOI: 10.1016/j.crvasa.2017.01.004

Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review

Irene Pescetelli, Eugenio Genovesi, Giulia Renda, Eligio Di Renzo, Raffaele De Caterina*
Institute of Cardiology and Center of Excellence on Aging - "G. d'Annunzio" University, Chieti, Italy

A 78-year-old woman with a history of ischemic heart disease and permanent atrial fibrillation, on treatment with warfarin, was admitted to the Emergency Department because of paroxysmal nocturnal dyspnoea. Instrumental findings indicated an early phase of acute heart failure. The latest INR value was 3.64, and previous available INR values were all within the therapeutic range (2-3). A transthoracic 2D echocardiographic examination showed left ventricular dilatation and a severe reduction in systolic function. An echogenic pedunculated mass was observed in the left atrium, adherent to the interatrial septum. Twelve hours later, the patient reported the acute onset of pain in the left arm. A thromboembolic occlusion of the left humeral artery was documented, and this was acutely treated with Fogarty embolectomy. In the first hour after this intervention, a series of relapsing thromboembolic events led to the final amputation of the arm. Warfarin was discontinued and treatment with dabigatran 150 mg BID enacted, followed by the disappearance of the thrombotic mass and clinical resolution.

Keywords: Anticoagulants; Dabigatran; Intracardiac thrombus; Non-vitamin K antagonist oral anticoagulants (NOACs); Systemic embolism; Thrombosis; Vitamin K antagonists; Warfarin

Received: May 19, 2016; Revised: December 31, 2016; Accepted: January 6, 2017; Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pescetelli I, Genovesi E, Renda G, Di Renzo E, De Caterina R. Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. Cor Vasa. 2017;59(3):e277-281. doi: 10.1016/j.crvasa.2017.01.004.
Download citation

References

  1. A.J. Camm, G.Y. Lip, R. De Caterina, et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association, Europace 14 (2012) 1385-1413. Go to PubMed...
  2. R. De Caterina, S. Husted, L. Wallentin, et al., Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease, Thrombosis and Haemostasis 110 (2013) 1087-1107. Go to original source... Go to PubMed...
  3. S. Mundi, A. Distante, R. De Caterina, [Genetic determinants of response to vitamin K antagonists], Giornale Italiano di Cardiologia (Rome) 15 (2014) 482-493.
  4. G. D'Andrea, R.L. D'Ambrosio, P. Di Perna, et al., A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin, Blood 105 (2005) 645-649. Go to original source... Go to PubMed...
  5. M. Moridani, L. Fu, R. Selby, et al., Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort, Clinical Biochemistry 39 (2006) 606-612. Go to original source... Go to PubMed...
  6. H. Heidbuchel, P. Verhamme, M. Alings, et al., EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary, European Heart Journal 34 (2013) 2094-2106. Go to original source... Go to PubMed...
  7. G.J. Hankey, J.W. Eikelboom, Dabigatran etexilate: a new oral thrombin inhibitor, Circulation 123 (2011) 1436-1450. Go to original source... Go to PubMed...
  8. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, et al., Dabigatran versus warfarin in patients with atrial fibrillation, New England Journal of Medicine 361 (2009) 1139-1151. Go to original source... Go to PubMed...
  9. O. Osinbowale, M. Al Malki, A. Schade, J.R. Bartholomew, An algorithm for managing warfarin resistance, Cleveland Clinic Journal of Medicine 76 (2009) 724-730. Go to original source... Go to PubMed...
  10. M.L. Hulse, Warfarin resistance: diagnosis and therapeutic alternatives, Pharmacotherapy 16 (1996) 1009-1017. Go to original source... Go to PubMed...
  11. M.J. Rieder, A.P. Reiner, B.F. Gage, et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, New England Journal of Medicine 352 (2005) 2285-2293. Go to original source... Go to PubMed...
  12. G.P. Aithal, C.P. Day, P.J. Kesteven, A.K. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet 353 (1999) 717-719. Go to original source... Go to PubMed...
  13. M. Balaban, V. Stanric, G. Rincic, et al., Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome - could new oral anticoagulants solve the problem? Acta Clinica Croatica 49 (2010) 469-477. Go to PubMed...
  14. G. Finazzi, R. Marchioli, V. Brancaccio, et al., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS), Journal of Thrombosis and Haemostasis 3 (2005) 848-853. Go to original source... Go to PubMed...
  15. M.A. Crowther, J.S. Ginsberg, J. Julian, et al., A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome, New England Journal of Medicine 349 (2003) 1133-1138. Go to original source... Go to PubMed...
  16. B.A. Hutten, M.H. Prins, M. Gent, et al., Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis, Journal of Clinical Oncology 18 (2000) 3078-3083. Go to original source... Go to PubMed...
  17. K. Seidl, M. Rameken, A. Drogemuller, et al., Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion. Final results of the Ludwigshafen Observational Cardioversion Study, Journal of the American College of Cardiology 39 (2002) 1436-1442. Go to original source... Go to PubMed...
  18. C.R. Thompson, C.E. Buller, L.A. Sleeper, et al., Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK? Journal of the American College of Cardiology 36 (2000) 1104-1109. Go to original source... Go to PubMed...
  19. C. Hammerstingl, B. Potzsch, G. Nickenig, Resolution of giant left atrial appendage thrombus with rivaroxaban, Thrombosis and Haemostasis 109 (2013) 583-584. Go to original source... Go to PubMed...
  20. P. Bernhardt, H. Schmidt, C. Hammerstingl, et al., Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging, American Journal of Cardiology 94 (2004) 801-804. Go to original source... Go to PubMed...
  21. R. De Caterina, A. John Camm, Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial, Europace 18 (2016) 6-11. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.